October 2026

Bryan Johnson is shipping an FDA-approved sex peptide — and the label has a different patient population

Bryan Johnson's Immortals platform lists bremelanotide — sold under the brand name Vyleesi by Pfizer — as the 'Arousal Peptide' in October 2026, available by prescription through the platform's telehealth physicians in both injection and nasal spray form. The [SF Standard reported in August 2026](https://sfstandard.com/2026/08/08/sf-s-sexmaxxing-scene-people-injecting-peptides-optimal-horniness/) on the Bay Area 'sexmaxxing' scene that placed PT-141 at the center of hacker-house peptide parties: a June event drew roughly 200 participants, and bremelanotide was among the substances being passed around. A quality-testing platform cited in that report found 43 of 114 gray-market PT-141 samples failed quality-control testing. None of that is the most interesting part. The most interesting part is that a peptide with a real FDA label — a label covering a specific disorder in a specific population of premenopausal women — is now being marketed as a general-purpose arousal enhancement for any adult who can complete a telehealth intake form. What Johnson's platform is building on is real, regulated medicine. The framing it is selling departs significantly from what the medicine is approved for.

The molecule

bremelanotide works in the brain's desire circuitry, not in the body's vascular plumbing

Bremelanotide is a cyclic heptapeptide that activates melanocortin receptors in the central nervous system — particularly the MC4R subtype, which is involved in appetite, energy balance, and the neural generation of sexual desire. The mechanism is structurally different from phosphodiesterase-5 inhibitors like sildenafil: those drugs work on vascular smooth muscle in the periphery, dilating blood vessels. Bremelanotide works upstream, modulating the circuitry that generates the subjective experience of wanting before any physical response occurs. The target condition is hypoactive sexual desire disorder — HSDD — defined as distressing, persistent low sexual desire not explained by relationship conflict, another medication, or another medical condition. The FDA approved bremelanotide as Vyleesi in June 2019 for that condition in premenopausal women. The drug's early research-peptide identity as PT-141 began with male erectile-dysfunction trials in the early 2000s, which is how the compound entered biohacking culture. The central desire mechanism is real and MC4R does appear to be meaningfully involved in it. The trials that resulted in an actual FDA approval enrolled one specifically defined patient population.

The pitch

the internet calls it a universal libido switch for any adult — which is about half correct

Bremelanotide arrived in compounding culture as PT-141 before it had a brand name, and those two identities now coexist in uncomfortable parallel. Vyleesi is a regulated drug with a prescribing label, formal pharmacovigilance, and a precisely defined indication. PT-141 is what people at San Francisco hacker-house parties self-administer before intimacy, and what telehealth platforms now prescribe to men who clicked through an intake form. The marketing language in both contexts converges on the same claim: this works at the source, in the brain, and applies to anyone seeking enhanced desire. Men in particular drive growing off-label demand, even though Vyleesi's approval excludes them and the male Phase 2 erectile-dysfunction program — which did show signal in PDE5 inhibitor non-responders — was discontinued rather than advanced to Phase 3. That gap between 'showed a Phase 2 signal' and 'FDA-approved for this population' is not semantic. It is where most internet discourse about PT-141 loses the thread, and where the Bryan Johnson marketing framing departs most clearly from what the clinical program actually established.

The data

the female HSDD trials were real and rigorous — the male program did not make it through Phase 2

Vyleesi's approval rests on two Phase 3 randomized controlled trials, RECONNECT-1 and RECONNECT-2, which enrolled premenopausal women with acquired, generalized HSDD and showed statistically significant improvements in satisfying sexual events and distress scores compared to placebo. The FDA approved the drug on that basis in 2019. The [PubMed literature trail for bremelanotide](https://pubmed.ncbi.nlm.nih.gov/?term=bremelanotide) includes the Phase 2 male erectile-dysfunction work — some signal in men who did not respond to PDE5 inhibitors — but that program did not advance. The American Urological Association noted in an April 2026 [clinical review of peptides for sexual dysfunction](https://auanews.net/issues/articles/2026/april-2026/peptides-for-sexual-dysfunction-what-clinicians-should-know) that real-world off-label use in men substantially outpaces the clinical evidence, and that nausea — which the [Vyleesi prescribing label](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bremelanotide) documents in approximately 40 percent of patients — is consistently absent from social media content about the compound. The drug also produces transient blood-pressure elevation, a cardiovascular pharmacology detail that high-dose or unsupervised off-label use routinely ignores.

Approved — PeptideFactCheck stance

the evidence tier is approved for a labeled use — it does not travel with the product to new ones

Bremelanotide carries PeptideFactCheck's Approved evidence tier because Vyleesi exists as a regulated, labeled drug with Phase 3 clinical evidence and a formal FDA approval behind it. The evidence-tier definition for Approved is specific: 'regulatory certainty for labeled uses, not a blank check for every claim.' That framing is doing real work here. The Vyleesi label covers premenopausal women with acquired, generalized HSDD. It does not cover men. It does not cover postmenopausal women. It does not cover performance enhancement, 'sexmaxxing,' or any telehealth-platform framing aimed at any adult seeking more desire. The gray-market PT-141 ecosystem adds a separate risk layer on top of the indication mismatch: compounded or unregulated products sit outside the tested formulation's quality controls, and the 43-of-114 quality-test failure rate makes that concrete rather than theoretical. Bryan Johnson's Immortals platform will expand public awareness of bremelanotide. It will not expand the scope of the FDA approval or the evidence behind the indications being marketed. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.